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Abstract
Background: Previous research suggested that single gene expression might be correlated with acute myeloid
leukemia (AML) survival. Therefore, we conducted a systematical analysis for AML prognostic gene expressions.
Methods: We performed a microarray-based analysis for correlations between gene expression and adult AML
overall survival (OS) using datasets GSE12417 and GSE8970. Positive findings were validated in an independent
cohort of 50 newly diagnosed, non-acute promyelocytic leukemia (APL) AML patients by quantitative RT-PCR
and survival analysis.
Results: Microarray-based analysis suggested that expression of eight genes was each associated with 1-year
and 3-year AML OS in both GSE12417 and GSE8970 datasets (p < 0.05). Next, we validated our findings in an
independent cohort of AML samples collected in our hospital. We found that ubiquitin-conjugating enzyme E2E1
(UBE2E1) expression was adversely correlated with AML survival (p = 0.04). Multivariable analysis showed that
UBE2E1high patients had a significant shorter OS and shorter progression-free survival after adjusting other known
prognostic factors (p = 0.03). At last, we found that UBE2E1 expression was negatively correlated with patients’
response to induction chemotherapy (p < 0.05).
Conclusions: In summary, we demonstrated that UBE2E1 expression was a novel prognostic factor in adult,
non-APL AML patients.
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Background
Acute myeloid leukemia (AML), characterized by expan-
sion of malignant myeloid precursor cells in peripheral
blood and bone marrow, is the most prevalent acute
leukemia in adults [1]. Several AML prognostic factors
have been reported, including patient age and cytogenetic
features [2, 3]. Interestingly, Metzeler et al showed that
high expression of lymphoid enhancer binding factor-1
(LEF1) is a favorable AML prognostic factor in non-acute
promyelocytic leukemia (APL) AML [4]. This study
provided insights on prognostic single gene expression in
AML. Therefore, we performed a systematical microarray-
based analysis to search gene expression that correlates
with AML overall survival (OS).
Methods
Microarray datasets download and analysis
We selected AML microarray datasets from Oncomine
(www.oncomine.com). Our selection criteria included (i)
microarray examining adult AML patient samples; (ii)
array data and patient survival data were both published;
(iii) microarray data quality; and (iv) microarray used
affymetrix array platform. Based on those selection
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criteria, we used GSE12417 and GSE8970 datasets for
our analysis [5, 6]. GSE12417 had 2 independent cohort of
samples, which were examined by affymetrix platforms
GPL570 and GPL96, respectively. Specifically, GSE12417-
GPL96 dataset included 163 adult AML patient gene
expression profiles, while GSE12417-GPL570 dataset
included 79 adult AML patient gene expression profiles.
The patients were previously untreated and received
cytarabine-based intensive induction and consolidation
chemotherapy in the trial [4, 5]. GSE8970 dataset used
affymetrix platform GPL96. GSE8970-GPL96 dataset in-
cluded 34 adult AML patient samples. The patients were
pretreated with tipifarnib [6]. The stem cell transplant-
ation status of those patients was not available. The same
probe ID system was used in all above datasets, enabling
results to be cross-compared. Gene expression profiles of
above datasets were downloaded from NCBI Gene
Expression Omnibus database. Clinic information of those
patients was downloaded from Oncomine.
Our algorithm of prognostic genes identification was
to identify prognostic genes in each microarray dataset
and then find common prognostic genes across all tested
datasets to avoid bias associated with single microarray
dataset. In one dataset, single gene expression in each
AML patient sample was presented by probe intensity.
Patients with a probe intensity value above or below the
median of all samples were categorized in probehigh and
probelow groups, respectively. Survival (1 year and
3 years) of the two groups was compared by the Mantel-
Cox test, and p < 0.05 was considered significant. Such
calculation was repeated for all genes (probes) in the
dataset by programming in R software to generate a list
of prognostic genes. Common genes across both datasets
were identified using the same probe ID (Fig. 1a).
Patient samples
Our validation cohort had 50 newly diagnosed AML pa-
tient samples collected at West China Hospital, Sichuan
University from 2010 to 2011. The inclusive criteria
include (1) adult patients (age > 18); (2) patients with
newly diagnosed AML except non-APL subtype; and (4)
no chemotherapy was administered before the study.
Bone marrow cell samples of the patients were collected
as described previously [7]. All patients were treated
Fig. 1 a Diagram showing the principal of microarray-based analysis. b OS according to high gene expression (genehigh, red) and low gene
expression (genelow, blue), analyzed using microarray datasets GSE12417 and GSE8970. GSE12417 had two independent cohorts, examined by
two microarray plateforms GPL570 and GPL96. c OS according to UBE2E1high (red) and UBE2E1low (blue) in validation cohort. d Relative UBE2E1
expression in patients with different performance status. e Relative UBE2E1 expression in patients with different responses to induction
chemotherapy, no response (NR) vs. complete response (CR). (*p < 0.05, **p < 0.01)
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based on the standard protocol including anthracyclines
plus cytarabine. The study was reviewed and approved
by the Central Ethics Committees of Institute of
Hematology/Blood Diseases Hospital, Chinese Academy
of Medical Sciences, and was filed in and permitted by
the Ethics Committees of West China Hospital, Sichuan
University.
Quantitative RT-PCR
Total RNA was extracted from patient bone marrow
cells with RNeasy Mini Kit (QIAGEN) according to the
manufacturer’s instruction. The expression of target
genes was analyzed by qPCR using SYBR green real-time
PCR system (Bio-Rad). The expression of housekeeping
gene GAPDH was used as an internal control. Primers
used were described in Table 1.
Statistical analysis
Patients’ characteristics between UBE2E1high and
UBE2E1low groups were analyzed using Fisher’s exact
test. The association between UBE2E1 expression as well
as other prognostic factors and patients’ survival was
investigated using univariable Cox regression and multi-
variable logistic regression analysis. All above statistical
analyses were performed in SPSS version 22 software.
Patient survival was graphed and analyzed using Graph-
Pad Prism 5 software with Mantel-Cox test (a function
of GraphPad Prism 5). A p < 0.05 was considered statisti-
cally significant.
Results
Microarray-based analysis for AML prognostic gene
expression
The microarray-based analysis showed that eight probes’
(genes’) expression was each associated with AML OS in
all datasets, from 1-year survival to 3-year OS (Fig. 1b).
These genes were ACOT11, FAXDC2, FECH, HBD,
KLF1, LEF1, SLC25A37, and UBE2E1 (Table 2 for chi-
square and p value). As shown in Fig. 1b, the expression
of FAXDC2, FECH, HBD, KLF1, LEF1, and SLC25A37
was a favorable prognostic factor for AML, while high
expression of UBE2E1 and ACOT11 was associated with
poor OS (p < 0.05). Furthermore, we compared the
target genes’ expression in normal BM vs. AML BM. At
least in two tested microarray datasets GSE13159 and
GSE1159, all target genes were aberrantly expressed in
AML: AML patients had averagely increased ACOT11
and UBE2E1 gene expression, while the patients had
lower expression of the other genes (Additional file 1:
Figure S1). In addition, we conducted multivariable ana-
lyses of the microarray datasets. The results revealed
that only UBE2E1, LEF1, and FECH1 were independent
prognostic factors in AML, despite the impact of the
Table 1 Probes for quantitative RT-PCR



















Table 2 Microarray-based analysis for AML overall survival related gene expression
GSE12417-GPL570 GSE12417-GPL96 GSE8970-GPL96
1-year 3-year 1-year 3-year 1-year
Gene name Probe ID Chi-square p value Chi-square p value Chi-square p value Chi-square p value Chi-square p value
ACOT11 214763_at 6.941523 0.00842 11.8655 0.00057 3.88562 0.0487 4.72131 0.02979 4.03782 0.04449
KLF1 210504_at 5.748149 0.01651 4.25163 0.03921 4.10844 0.04267 9.61817 0.00193 5.14706 0.02329
LEF1 221558_s_at 14.72791 0.00012 13.5199 0.00024 7.77776 0.00529 11.0276 0.0009 5.14706 0.02329
FECH 203115_at 11.52174 0.00069 9.90671 0.00165 7.00522 0.00813 10.0492 0.00152 5.14706 0.02329
FAXDC2 220751_s_at 5.786984 0.01615 7.59189 0.00586 4.01214 0.04517 7.41339 0.00647 5.14706 0.02329
HBD 206834_at 11.87311 0.00057 7.12887 0.00759 4.42625 0.03539 6.57289 0.01035 5.14706 0.02329
SLC25A37 221920_s_at 5.786984 0.01615 5.01703 0.0251 4.59061 0.03215 6.62943 0.01003 5.14706 0.02329
UBE2E1 212519_at 4.114544 0.04252 4.50706 0.03376 6.25573 0.01238 5.73031 0.01667 4.03782 0.04449
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Table 3 Multivariable analysis of target genes in microarray datasets
GSE8970-GPL96 GSE12417-GPL96 GSE12417-GPL570
OS PFS OS OS
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
ACOT11 ACOT11 expression, high vs. low 0.658(0.296,1.462) 0.304 0.636(0.287,1.405) 0.263 1.445(0.970,2.154) 0.07 1.809(1.009,3.243) 0.047
Age, per 10-year increase 1.201(0.704,2.048) 0.501 1.212(0.716,2.053) 0.474 1.295(1.126,1.490) <0.001 1.400(1.088,1.800) 0.009
Sex, male vs. female 1.326(0.473,3.717) 0.592 1.369(0.488,3.838) 0.551 NA NA NA NA
Prior myelodysplastic syndrome 0.685(0.270,1.741) 0.427 0.711(0.281,1.795) 0.470 NA NA NA NA
Organ dysfunction 1.162(0.490,2.753) 0.733 1.253(0.536,2.930) 0.603 NA NA NA NA
FAB subtype NA NA NA NA 0.879(0.773,0.999) 0.048 0.956(0.778,1.174) 0.667
FAXDC2 FAXDC2 expression, high vs. low 0.922(0.420.2.023) 0.839 1(0.462,2.166) >0.99 0.869(0.590,1.280) 0.477 0.791(0.444,1.406) 0.424
Age, per 10-year increase 1.185(0.685,2.051) 0.544 1.182(0.688,2.030) 0.545 1.278(1.114,1.466) <0.001 1.382(1.074,1.778) 0.012
Sex, male vs. female 1.553(0.589,4.094) 0.373 1.662(0.636,4.339) 0.300 NA NA NA NA
Prior myelodysplastic syndrome 0.681(0.265,1.753) 0.426 0.698(0.273,1.783) 0.452 NA NA NA NA
Organ dysfunction 1.094(0.471,2.539) 0.835 1.164(0.509,2.662) 0.719 NA NA NA NA
FAB subtype NA NA NA NA 0.862(0.762,0.976) 0.019 0.965(0.782,1.192) 0.744
FECH FECH expression, high vs. low 0.363(0.149,0.883) 0.025 0.390(0.163,0.934) 0.034 0.566(0.382,0.838) 0.005 0.424(0.235,0.764) 0.004
Age, per 10-year increase 1.050(0.625,1.762) 0.854 1.066(0.639,1.779) 0.806 1.277(1.109,1.470) 0.001 1.410(1.095,1.817) 0.008
Sex, male vs. female 1.932(0.734,5.089) 0.183 1.988(0.763,5.181) 0.160 NA NA NA NA
Prior myelodysplastic syndrome 0.452(0.169,1.204) 0.112 0.486(0.184,1.284) 0.146 NA NA NA NA
Organ dysfunction 1.684(0.653,4.343) 0.281 1.781(0.697,4.554) 0.228 NA NA NA NA
FAB subtype NA NA NA NA 0.855(0.757,0.967) 0.013 0.978(0.790,1.210) 0.837
HBD HBD expression, high vs. low 0.396(0.166,0.942) 0.036 0.430(0.183,1.011) 0.053 0.528(0.356,0.783) 0.001 0.479(0.266,0.862) 0.014
Age, per 10-year increase 1.015(0.594,1.732) 0.957 1.035(0.610,1.756) 0.898 1.294(1.126,1.487) <0.001 1.363(1.070,1.738) 0.012
Sex, male vs. female 2.086(0.738,5.898) 0.166 2.125(0.765,5.905) 0.148 NA NA NA NA
Prior myelodysplastic syndrome 0.595(0.221,1.605) 0.305 0.627(0.236,1.666) 0.349 NA NA NA NA
Organ dysfunction 1.479(0.595,3.681) 0.400 1.576(0.637,3.895) 0.325 NA NA NA NA
FAB subtype NA NA NA NA 0.861(0.763,0.973) 0.016 0.995(0.805,1.229) 0.96
KLF1 KLF1 expression, high vs. low 0.457(0.208,1.000) 0.050 0.429(0.198,0.927) 0.031 0.560(0.379,0.829) 0.004 0.581(0.325,1.037) 0.066
Age, per 10-year increase 1.061(0.609,1.849) 0.834 1.062(0.613,1.840) 0.830 1.281(1.111,1.476) 0.001 1.382(1.087,1.756) 0.008
Sex, male vs. female 1.928(0.693,5.362) 0.209 2.064(0.742,5.738) 0.165 NA NA NA NA
Prior myelodysplastic syndrome 0.562(0.204,1.547) 0.265 0.574(0.208,1.584) 0.284 NA NA NA NA
Organ dysfunction 1.184(0.492,2.845) 0.706 1.259(0.530,2.994) 0.602 NA NA NA NA
FAB subtype NA NA NA NA 0.853(0.755,0.963) 0.011 0.976(0.791,1.204) 0.821
LEF1 LEF1 expression, high vs. low 0.273(0.117,0.638) 0.003 0.287(0.126,0.655) 0.003 0.605(0.407,0.901) 0.013 0.382(0.209,0.700) 0.002
Age, per 10-year increase 1.328(0.789,2.236) 0.285 1.342(0.802,2.245) 0.263 1.259(1.094,1.449) 0.001 1.423(1.099,1.843) 0.007
Sex, male vs. female 2.475(0.793,7.723) 0.119 2.511(0.821,7.673) 0.106 NA NA NA NA
Prior myelodysplastic syndrome 0.554(0.208,1.479) 0.239 0.595(0.225,1.573) 0.295 NA NA NA NA
Organ dysfunction 1.021(0.406,2.586) 0.966 1.109(0.450,2.733) 0.823 NA NA NA NA
FAB subtype NA NA NA NA 0.870(0.766,0.988) 0.031 1.031(0.829,1.282) 0.785
SLC25A37 SLC25A37 expression, high vs.
low
0.312(0.117,0.827) 0.019 0.294(0.111,0.782) 0.014 0.540(0.360,0.808) 0.003 0.616(0.345,1.101) 0.102
Age, per 10-year increase 0.963(0.554,1.674) 0.894 0.961(0.557,1.661) 0.888 1.292(1.122,1.488) <0.001 1.389(1.084,1.778) 0.009
Sex, male vs. female 1.431(0.548,3.737) 0.465 1.474(0.568,3.828) 0.425 NA NA NA NA
Prior myelodysplastic syndrome 0.336(0.106,1.065) 0.064 0.332(0.105,1.058) 0.062 NA NA NA NA
Organ dysfunction 1.377(0.573,3.310) 0.475 1.494(0.629,3.552) 0.363 NA NA NA NA
FAB subtype NA NA NA NA 0.897(0.792,1.015) 0.086 0.983(0.796,1.214) 0.872
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patient age, FAB subtype as well as other prognostic fac-
tors (Table 3). Interestingly, among those three identified
prognostic-related single genes, high expression of LEF1
has already been reported as a favorable prognostic
factor in cytogenetically normal adult AML [4].
High expression of UBE2E1 is a poor prognostic factor
in AML
We validated our findings in an independent cohort of 50
AML patients (median age 43). Target gene expression
was analyzed by quantitative RT-PCR. Based on median
gene expression, we divided our patients into two study
groups, genehigh and genelow groups. The survival analysis
showed that out of eight genes identified by microarray
studies, the expression of only one gene UBE2E1 (ubuqui-
tin-conjugating enzyme E2E1) was associated with AML
OS in our validation cohort, and this gene was one of the
three genes with independent prognostic value on multi-
variable analysis in the training set. The UBE2E1high group
had a markedly shorter OS compared with UBE2E1low
group (p = 0.02; Fig. 1c). Expression of the other seven
genes was not associated with AML prognosis in our
study (p > 0.05; Additional file 1: Figure S2). We could not
detect KLF1 expression in AML patient samples, although
the qPCR primers for this gene were validated.
Next, we performed multivariable analysis to verify the
prognostic significance of UBE2E1 expression in our val-
idation cohort. The patient characteristics of UBE2E1high
and UBE2E1low groups are shown in Table 4. No signifi-
cant difference in patient characteristics, such as age,
FAB subtypes, WBC count, BM blast percentages, gene
mutations, was found between the two groups. We
found no difference in patients’ treatment between those
two groups (Table 5). UBE2E1high patients had a short
OS (p = 0.04) as well as a short progression-free survival
(p = 0.03) compared with UBE2E1low patients after
adjusting for the impact of other prognostic factors
including patient age, gender, performance status, and
response to induction chemotherapy (Table 6).
UBE2E1 expression and its association with
chemotherapy response
Finally, in our validation cohort, low UBE2E1 expression
was associated with a better performance status in the
Table 3 Multivariable analysis of target genes in microarray datasets (Continued)
UBE2E1 UBE2E1 expression, high vs. low 3.5(1.08,11.33) 0.04 3.9(1.27,11.98) 0.02 1.28(0.77,2.12) 0.04 2.02(1.8,3.79) 0.03
Age, per 10-year increase 1.04(0.96,1.13) 0.32 1.04(0.96,1.12) 0.35 1.02(1.00,1.04) 0.03 1.36(1.07,1.73) 0.01
Sex, male vs. female 1.22(0.39,3.81) 0.74 1.51(0.52,4.42) 0.45 NA NA NA NA
Prior myelodysplastic syndrome 0.83(0.25,2.72) 0.75 0.88(0.29,2.71) 0.83 NA NA NA NA
Organ dysfunction 0.96(0.33,2.81) 0.94 0.99(0.37,2.6) 0.98 NA NA NA NA
FAB subtype NA NA NA NA 0.87(0.74,1.0) 0.1 1.06(0.85,1.32) 0.61
NA not available






Median age 43.08 43.25 0.567
Female, no. (%) 10(40) 13(52) 0.395
Secondary or treatment-
related AML, no. (%)
2(8) 2(8) >0.99







Median WBC, 109/L (range) 6.83(0.3–244.38) 23.88(0.68–366) 0.289




CEBPA mutated, no. (%) 2(8) 5(20) 0.179
Missing date 1 3
NPM1 mutated, no. (%) 2(8) 4(16) 0.327
Missing date 1 3
IDH1 mutated, no. (%) 0 0 >0.99
Missing date 1 3
FLT3-TKD mutated, no. (%) 0 1(4) 0.296
Missing date 1 3
FLT3-ITD mutated, no. (%) 0 2(4) 0.149
Missing date 1 3
AML1/ETO mutated, no. (%) 4(16) 6(24) 0.389
Missing date 1 3
C-KIT D816V mutated, no. (%) 1(4) 2(8) 0.504
Missing date 1 3
CBEB-MYH11 mutated, no. (%) 2(8) 3(12) 0.568
Missing date 1 3
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patients (Fig. 1d; p < 0.05). We also found that UBE2E1
expression was associated with response to induction
chemotherapy. Patients who had relatively higher
UBE2E1 expression were more likely to achieve no
response (NR) to chemotherapy while patients who had
lower UBE2E1 expression were more likely to enter
complete remission (CR) (Fig. 1e; p < 0.05). This result
suggests that UBE2E1 expression may be a possible
predictor for chemotherapy response in AML patients.
Discussion
In this study, we performed a genome-wide screening to
identify gene expression that correlate with adult AML
OS. The gene expression profiles (GEPs) from 2 inde-
pendent datasets of patient samples were used in our
analysis. The correlation of each gene expression and
AML OS was calculated by a program coded by R soft-
ware. Only gene identified with statistical significance in
both datasets was considered as positive results for
further test. By this strategy of analysis, we identified 8
AML prognostic genes. Next, we tested our findings
using an independent cohort of 50 AML samples. Our
result suggested that although several genes, such as
HBD and ACOT11, had trend correlation, only one gene,
UBE2E1, was statistically correlated with AML OS in
our validation cohort. The negative findings of other 7
genes in our validation cohort might be caused by the
relatively small number of patients. In addition, we no-
ticed that the patients in microarray-testing cohort and
our validation cohort had different ethnic backgrounds.
Further studies might be necessary to draw a more
confirmative conclusion.
Mounting evidence has shown that AML is highly
heterogeneous and dynamic [8]. The heterogeneous
entity of AML emerges from the disease genetic basis,
leukemogenesis, pathophysiology, and prognosis. How-
ever, cluster of gene expression signature [5], or even
single gene expression [4], has been shown to correlate
with AML prognosis. Therefore, what is the interpre-
tation of prognostic single gene expression, such as
UBE2E1 and LEF1, in AML? We hypothesized that
different subgroups of AML, with discrete driver muta-
tions, might have similar epigenetic effectors’ upregula-
tion/downregulation, which correlate with patient’s
survival. We also hypothesized that in different prognosis-
relevant AML subgroups, the effectors have patterned
expression. To test these hypotheses, we performed
another microarray-based analysis for UBE2E1 expression
in AML with complex karyotype vs. normal karyotype,
FLT3 mutation vs. wildtypeFLT3, and NPM1 mutation vs.
wildtypeNPM1. We selected those genetic abnormalities
because they have high frequency of occurrence in AML
and correlate with the patient clinical outcome: patients
with complex karyotype or FLT3 mutation had poor treat-
ment outcome, while patients with NPM1 mutation had
good treatment outcome [8]. As shown in Additional
file 1: Table S1, complex karyotype or FLT3-mutated
AML had relatively high UBE2E1 expression, com-
pared with normal karyotype or wildtype FLT3 AML,
respectively. NPM1-mutated AML had relatively low
UBE2E1 expression. These preliminary findings might
indicate that UBE2E1 have patterned expressions,
which was well matched with AML classification
despite of different genetic basis.
Protein ubiquitination was accomplished by sequential
action of enzymes E1, E2, and E3. Specifically, E2 trans-
ferred E1-activated ubiquitin to E3, an ubiquitin ligase,
and formed an isopeptide bond between ubiquitin and
protein substrate. UBE2E1 was a member of ubiquitin-
conjugating enzyme E2 class. Zhu et al. showed that
UBE2E1 regulated HOX gene expression by ubiquitinat-
ing histones [9]. Thus, UBE2E1 might play a regulatory
Table 5 Characteristic of AML patients treatment in validation
cohort
Variable UBE2E1high UBE2E1low p








Table 6 Multivariable analysis in validation cohort
OS PFS
HR (95% CI) p HR (95% CI) p
UBE2E1 expression, high vs. low 3.227(1.05,9.852) 0.040 3.818(1.616,12.553) 0.027
Age, per 10-year increase 1.666(1.112,2.498) 0.013 1.536(1.02,2.313) 0.040
Sex, male vs. female 0.628(0.214,1.84) 0.396 0.559(0.183,1.71) 0.308
Performance status 0.727(0.374,1.41) 0.345 0.683(0.344,1.358) 0.277
Induction chemo-response 1.472(0.845,2.566) 0.172 1.51(0.853,2.672) 0.157
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role in cell by selectively ubiquitinating target proteins.
The function of UBE2E1 in cell signaling is still largely
unknown. However, the regulation of UBE2E1 on HOX
gene might be a key to understand the prognostic role of
UBE2E1 in AML. HOX gene is a family of highly
conserved homeodomain transcription factor genes [10].
There are 39 HOX genes, belonging to 4 gene clusters,
in human. Previous work has shown that HOX genes are
aberrantly expressed in AML [11, 12]. Animal study
indicated that overexpression HOX gene, HOXA10 and
HOXA9, promoted AML leukemogenesis [13, 14]. To
identify potential UBE2E1 downstream HOX genes, we
started with microarray datasets. We found co-expression
of UBE2E1 with HOXA11 in AML. We also examined
HOXA11 and UBE2E1 co-expression in our validation co-
hort (Additional file 1: Figure S3). Interestingly, a recent
publication suggested that HOXA11 expression correlated
with glioblastoma patient treatment responses and
prognosis [15]. Thus, it is highly possible that UBE2E1
regulates AML chemoresistance through HOXA11.
In our study, we found co-expression of UBE2E1 with
HOX family gene, HOXA11, in AML. Therefore, we hy-
pothesized that UBE2E1 regulates HOXA11 gene expres-
sion in AML, and HOXA11 transcription factor level
might be relevant to AML treatment resistance. We are
actively conducting more mechanistic studies to demon-
strate the role of UBE2E1 in AML.
Conclusions
In conclusion, we performed a genome-wide, microarray-
based analysis for gene expressions that correlated with
AML survival, and found 8 candidate genes. We further
tested these genes in an independent validation cohort of
50 AML samples, and identified that UBE2E1 expression
adversely correlated with AML prognosis.
Additional file
Additional file 1: Figure S1. Aberrant target gene expression in AML.
AML patient samples microarray datasets GSE13159 and GSE1159 were
downloaded from NCBI. Normal samples in those datasets were bone
marrow cells or peripheral blood mononuclear cells (PBMCs) from
healthy donors. Target gene expression in normal samples vs. AML
patient samples were plotted and compared by the Student’s t test
(**p < 0.01). Figure S2. Target gene correlation with patient survival in
validation cohort. Figure S3. Co-expression of UBE2E1 and HOXA11 in
AML. Table S1. UBE2E1 expression in AML subgroups. (PPTX 202 kb)
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